{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:16:35Z","timestamp":1788405395582,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T00:00:00Z","timestamp":1765670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["ISS 20177429"],"award-info":[{"award-number":["ISS 20177429"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["FD003902"],"award-info":[{"award-number":["FD003902"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["FD005114"],"award-info":[{"award-number":["FD005114"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00198-025-07755-z","type":"journal-article","created":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T21:11:19Z","timestamp":1765746679000},"page":"203-212","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bone density and remodeling after discontinuation of sequential therapy for premenopausal idiopathic osteoporosis"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0641-5747","authenticated-orcid":false,"given":"Adi","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mafo","family":"Kamanda-Kosseh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragyie","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanchita","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Shiau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivelisse","family":"Colon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Bucovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan M.","family":"Lappe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Shane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,14]]},"reference":[{"key":"7755_CR1","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1210\/jc.2011-1387","volume":"96","author":"A Cohen","year":"2011","unstructured":"Cohen A, Dempster DW, Recker RR et al (2011) Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 96:3095\u20133105","journal-title":"J Clin Endocrinol Metab"},{"key":"7755_CR2","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1210\/jc.2012-2099","volume":"97","author":"A Cohen","year":"2012","unstructured":"Cohen A, Lang TF, McMahon DJ et al (2012) Central QCT reveals lower volumetric BMD and stiffness in premenopausal women with idiopathic osteoporosis, regardless of fracture history. J Clin Endocrinol Metab 97:4244\u20134252","journal-title":"J Clin Endocrinol Metab"},{"key":"7755_CR3","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1210\/jc.2009-0996","volume":"94","author":"A Cohen","year":"2009","unstructured":"Cohen A, Liu XS, Stein EM, McMahon DJ, Rogers HF, Lemaster J, Recker RR, Lappe JM, Guo XE, Shane E (2009) Bone microarchitecture and stiffness in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 94:4351\u20134360","journal-title":"J Clin Endocrinol Metab"},{"key":"7755_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00198-011-1560-y","volume":"23","author":"A Cohen","year":"2012","unstructured":"Cohen A, Recker RR, Lappe J et al (2012) Premenopausal women with idiopathic low-trauma fractures and\/or low bone mineral density. Osteoporos Int 23:171\u2013182","journal-title":"Osteoporos Int"},{"key":"7755_CR5","doi-asserted-by":"publisher","first-page":"e3540","DOI":"10.1210\/clinem\/dgaa489","volume":"105","author":"A Cohen","year":"2020","unstructured":"Cohen A, Shiau S, Nair N et al (2020) Effect of teriparatide on bone remodeling and density in premenopausal idiopathic osteoporosis: a phase II trial. J Clin Endocrinol Metab 105:e3540-3556","journal-title":"J Clin Endocrinol Metab"},{"key":"7755_CR6","doi-asserted-by":"publisher","first-page":"e1528","DOI":"10.1210\/clinem\/dgab850","volume":"107","author":"E Shane","year":"2022","unstructured":"Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A (2022) Denosumab after teriparatide in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab 107:e1528\u2013e1540","journal-title":"J Clin Endocrinol Metab"},{"key":"7755_CR7","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/jbmr.3337","volume":"33","author":"SR Cummings","year":"2018","unstructured":"Cummings SR, Ferrari S, Eastell R et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190\u2013198","journal-title":"J Bone Miner Res"},{"key":"7755_CR8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1210\/jc.2019-00221","volume":"104","author":"R Eastell","year":"2019","unstructured":"Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D (2019) Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline. J Clin Endocrinol Metab 104:1595\u20131622","journal-title":"J Clin Endocrinol Metab"},{"key":"7755_CR9","doi-asserted-by":"crossref","unstructured":"Tsourdi E, Zillikens MC, Meier C et al (2021) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab\u00a0106(1):264\u2013281","DOI":"10.1210\/clinem\/dgaa756"},{"key":"7755_CR10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae240","author":"M Kamanda-Kosseh","year":"2024","unstructured":"Kamanda-Kosseh M, Shiau S, Agarwal S et al (2024) Bisphosphonates maintain BMD after sequential teriparatide and denosumab in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgae240","journal-title":"J Clin Endocrinol Metab"},{"key":"7755_CR11","doi-asserted-by":"publisher","first-page":"116764","DOI":"10.1016\/j.bone.2023.116764","volume":"172","author":"G Liebich","year":"2023","unstructured":"Liebich G, Lamy O, Aubry-Rozier B, Gonzalez-Rodriguez E (2023) Maintenance of bone resorption markers in the low premenopausal range during the year following denosumab discontinuation is associated to bone density preservation. The ReoLaus study. Bone 172:116764","journal-title":"Bone"},{"key":"7755_CR12","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS Solling","year":"2020","unstructured":"Solling AS, Harslof T, Langdahl B (2020) Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35:1858\u20131870","journal-title":"J Bone Miner Res"},{"key":"7755_CR13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39:58\u201374","journal-title":"Adv Ther"},{"key":"7755_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","volume":"21","author":"AS Solling","year":"2023","unstructured":"Solling AS, Tsourdi E, Harslof T, Langdahl BL (2023) Denosumab discontinuation. Curr Osteoporos Rep 21:95\u2013103","journal-title":"Curr Osteoporos Rep"},{"key":"7755_CR15","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1002\/jbmr.4305","volume":"36","author":"AS Solling","year":"2021","unstructured":"Solling AS, Harslof T, Langdahl B (2021) Treatment with zoledronate subsequent to denosumab in osteoporosis: a 2-year randomized study. J Bone Miner Res 36:1245\u20131254","journal-title":"J Bone Miner Res"},{"key":"7755_CR16","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1007\/s00198-024-07213-2","volume":"35","author":"JN Tsai","year":"2024","unstructured":"Tsai JN, Jordan M, Lee H, Leder BZ (2024) One versus 2 years of alendronate following denosumab: the CARD extension. Osteoporos Int 35:2225\u20132230","journal-title":"Osteoporos Int"},{"key":"7755_CR17","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res 34:2220\u20132228","journal-title":"J Bone Miner Res"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07755-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-025-07755-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-025-07755-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:37:29Z","timestamp":1769510249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-025-07755-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,14]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7755"],"URL":"https:\/\/doi.org\/10.1007\/s00198-025-07755-z","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,14]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AC, ES, and JML have received research grant support from Amgen. MKK, RR, SA, JB, SS, IC, and MB have participated in implementing the research protocol that was conducted with research grant support from Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}